Major depressive disorder (MDD) has a lifetime incidence of 10% to 15%.1 The main treatment options include pharmacological and psychological interventions, with many patients receiving combination treatment. Although randomized clinical trials (RCTs) have established the efficacy of antidepressants,2 acute and long-term effectiveness is limited, and one-third of patients develop treatment resistance. New interventions are needed in the field and this Viewpoint examines novel interventions, with a specific focus on exercise, nutrition, and ketamine.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Köhler-Forsberg O, Cusin C, Nierenberg AA. Evolving Issues in the Treatment of Depression. JAMA. 2019;321(24):2401–2402. doi:10.1001/jama.2019.4990
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.